Replies to post #1216 on Precious Metals

[bladerunner1717]

Insider buys at MEIP


MEI Pharma CFO bought 12,500 shares

CFO Brian G. Drazba bought 12,500 shares for $1.6 per share on Dec. 19. Since then, the stock price has increased by 17.5%. MEI Pharma has a market cap of $138.471 million and its shares were traded around $1.88. The company has a price-sales ratio of 24.42.

MEI Pharma announced its third-quarter results with revenue of $1.16 million and gross profit of $469,000, while the net loss was $2.99 million. The 2019 total revenue was $4.92 million, a 203% increase from 2018. The gross profit was $652,000, a 137% increase from the year prior. The net loss was $16.82 million.

CEO Daniel P. Gold bought 18,750 shares for $1.6 per share on Dec. 19. Director Thomas C. Reynolds bought 10,000 shares and Director Frederick W. Driscoll bought 62,500 shares. Since then, the stock price has increased by 17.5%.

Bladerunner

[bladerunner1717]

MEIP reports 2nd quarter fiscal year results. (Not a single word about Helsinn or the Phase III with Pracinostat in AML being run by Helsinn.)

https://finance.yahoo.com/news/mei-pharma-reports-fiscal-second-210200882.html


MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights
PR Newswire PR Newswire•February 6, 2020
-- MEI Starts Fiscal Third Quarter of 2020 with ~$104 Million in Cash --

-- High Response Rate, Durability of Response and Tolerability of ME-401 Drives Decision to Consolidate Enrollment to Intermittent Dosing Schedule in the TIDAL Study Intended to Support an Accelerated Approval Marketing Application --

SAN DIEGO, Feb. 6, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its second quarter ended December 31, 2019.

"We're off to a good start in calendar year 2020. Our pipeline of clinical oncology candidates continues to advance, and the successful equity offering this past December gives us added resources to execute on our clinical strategy through key value-creating inflection points," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "We have several important milestones across our pipeline in 2020 including completing enrollment in the ME-401 TIDAL study, data updates from the Phase 1b study of ME-401 administered as a monotherapy and in combination with other agents to treat patients with B-cell malignancies, one year survival data from the Phase 2 pracinostat study in patients with MDS, and voruciclib updates in patients with AML and B-cell malignancies."

Dr. Gold added, "We remain very encouraged by the ME-401 clinical program; the maturing data on the intermittent dosing schedule in the Phase 1b study continue to demonstrate high overall response rates and durable responses, and the intermittent schedule also continues to be well tolerated. Based on the strength of the data set from these intermittent schedule patients, the TIDAL study was amended to consolidate the remaining study enrollment into the intermittent dosing arm. We expect to complete enrollment in the TIDAL study this summer and plan a submission for accelerated approval with the FDA based on the results of this study."

Recent Highlights

In December 2019, the Company completed a public offering of common stock resulting in net proceeds to the Company of approximately $48.5 million.

In December 2019, the Company amended the study protocol for TIDAL (Trials of PI3K DeltA in Non-Hodgkin's Lymphoma), the Phase 2 trial evaluating ME-401 in patients with relapsed or refractory follicular lymphoma ("FL"). TIDAL is intended to support an accelerated approval marketing application with the FDA.

In October 2019, the Company reported updated data from the ongoing Phase 1b study of ME-401, an investigational selective oral inhibitor of phosphatidylinositol 3-kinase ("PI3K") delta. The data demonstrate:

Fiscal Second-Quarter Fiscal Year 2020 Financial Results

As of December 31, 2019, MEI had $103.9 million in cash, cash equivalents and short-term investments, with no outstanding debt.
For the quarter ended December 31, 2019, cash used in operations was $10.5 million, compared to $7.2 million for 2018.

Research and development expenses were $8.3 million for the quarter ended December 31, 2019, compared to $9.1 million for 2018. The decrease was primarily related to decreased drug manufacturing costs associated with ME-401.

General and administrative expenses were $4.2 million for the quarter ended December 31, 2019, compared to $3.8 million for 2018. The increase primarily relates to increased headcount and increased professional services expenses to support our activities.

Revenue was $1.0 million for the quarter ended December 31, 2019, compared to revenue of $2.0 million for the quarter ended December 31, 2018. Revenue resulted from the recognition of fees allocated to research and development activities related to the Helsinn and Kyowa Kirin License Agreements. During the quarter ended December 31, 2018, revenue also included $0.9 million from transfer of the license to Kyowa Kirin.

Net loss was $20.2 million, or $0.26 per share, for the quarter ended December 31, 2019, compared to net income of $12.0 million, or $0.17 per share for 2018. Net loss increased primarily as a result of a non-cash expense in the current quarter and a non-cash gain in the prior quarter related to changes in the fair value of the warrant liability associated with the May 2018 financing. The Company had 105,998,677 shares of common stock outstanding as of December 31, 2019, compared with 71,131,486 shares as of December 31, 2018.

The adjusted net loss for the quarter ended December 31, 2019, excluding a non-cash expense related to changes in the fair value of the warrants (a non-GAAP measure), was $11.8 million, compared to an adjusted net loss of $11.4 million for 2018.

Bladerunner